Addition of the PCSK9 inhibitor evolocumab to statin therapy after cardiac bypass surgery did not improve 24-month graft patency in the NEWTON-CABG CardioLink-5 trial. Subodh Verma, MD, cardiac ...
Aims: Coronary artery bypass grafts (CABGs) are increasingly performed in elderly patients. Risk factors and outcomes are poorly described for those undergoing noncardiac surgery within 1 year after ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results